Skip to main content

Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About
Trending Topics
    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Entertainment & Media
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor, Employment, and Benefits
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations
    Industries

    View All

    • Aviation
    • Cannabis
    • Consumer
    • Energy
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Nonprofit Organizations
    • Real Estate
    • Sports & Stadiums
    • Technology
    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Environmental, Social, and Governance (ESG)

      We help clients create positive return on investments in people, products, and the planet.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    • Women in Dealmaking

      We provide strategic counsel on complex corporate transactions and unite dynamic women in the dealmaking arena.

    1. Home
    2. Insights
    3. Alerts
    4. Clinical research during coronavirus (COVID-19) pandemic

      Alerts

    Alert / Healthcare

    Clinical research during coronavirus (COVID-19) pandemic

    April 6, 2020

    LinkedInX (Twitter)EmailCopy URL

    By Jason Chimon, Gabrielle Goldstein, PhD, Jill Gordon and Seth Levy

    The United States Food and Drug Administration (FDA) and National Institutes of Health (NIH) released guidance to ensure the safety of trial participants, maintain compliance with good clinical practice, and minimize risks to trial integrity during the COVID-19 pandemic. Here is what you need to know regarding conducting clinical research during the pandemic.

    FDA

    The pandemic will impact clinical trials due to governmental quarantines, investigative site closures, travel restrictions, and disruptions to supply chains. Recognizing that these challenges may require unavoidable protocol deviations, the FDA provides in its guidance a number of measures for trial sponsors to consider.

    Safety of subjects

    Sponsors should consider the impact of each circumstance and deviation on the safety of subjects, and keep subjects informed of all study changes and monitoring plans that could affect them. In consultation with investigators and IRBs, sponsors should determine whether trial subject safety requires continuance of the protocol, discontinuation of use of the study product, or ceasing participation in the study altogether.

    Alternative methods for the study

    In light of travel restrictions and quarantines, sponsors should evaluate whether alternative methods of safety assessments can be used in lieu of in-person visits while assuring subject safety. Such methods include:

    • Phone calls
    • Virtual visits
    • Alternative locations for certain aspects of the trial, such as local labs or imaging centers
    • For study products that are administered in a health care setting, sponsors can consult FDA review divisions on plans for alternative administration—such as home nursing or through trained but non-study personnel. The FDA stresses that regulatory requirements for the investigational drug accountability remain in place.

    Safety monitoring

    Additional safety monitoring for study subjects that no longer have access to the study product or site should be considered. Also consider optimizing use of central and remote monitoring programs for site oversight when on-site monitoring is no longer possible.

    Modifying protocols

    Processes should be adopted or modified to account for the nature of the protocol and local situation. For example, sponsors can consider whether it is appropriate that some assessments for ongoing trials be delayed, or to halt recruitment and/or withdraw study participants if the study can no longer be properly conducted. In implementing any such changes, sponsors should adhere to the protocol to the extent possible, and the reason for any contingency measures should be well-documented by sponsors and investigators, including the duration of these changes, the study subjects impacted, and the way in which they were impacted. For all changes, sponsors are encouraged to engage with IRBs as soon as possible when coronavirus-related changes are necessary or anticipated.

    Missing data

    If COVID-19-related measures result in missing data or information, capture specific information in the case report form explaining the reason for the missing data. This information will be summarized in the clinical study report. Consult with the applicable FDA review division where protocol amendments will alter data management or statistical analysis plans. Such plans should address how protocol deviations related to coronavirus will be handled in the analyses.

    Policies and procedures

    Sponsors, investigators, and IRBs should consider establishing or revising policies and procedures to describe the approaches to be taken as a result of the pandemic.

    NIH

    Echoing the FDA, the NIH urges that safety is their primary concern. Institutions should take all steps necessary to protect the health and welfare of subjects and research staff. Examples include:

    • Limiting study visits to those needed for participant safety or coincident with clinical care
    • Conducting virtual study visits
    • Arranging flexibilities for required laboratory tests or imaging needed for safety monitoring to occur at local laboratories or clinics
    • Canceling large gatherings of 50 or more people
    • Limiting or suspending unnecessary travel

    The NIH guidance also allows for additional extensions to study periods beyond those already provided by policy, and notes that recipients should contact the awarding institute or center regarding the need for an extension. Additional funding may also be available where existing grants do not cover the unanticipated costs incurred as a result of the pandemic.

    Conclusion

    Clinical research is important in the response to the pandemic. At the same time subject safety is paramount. Health care sites might not be appropriate sites for research and alternative methods during the pandemic. Alternative sites or patient safety plans may be appropriate. Review current research protocols and activities and implement policies and procedures related to pandemic preparedness and response for clinical research.

    For more information on the content of this alert, please contact our Coronavirus Response team

    Practices

    HealthcareLife Sciences

    Industries

    Healthcare

    Insights And Happenings

    • Alert

      New York’s OPWDD releases interim COVID-19 guidance regarding community habilitation and care planning activities

      May 11, 2020
    • Alert

      An HK $80 billion employment support scheme for eligible employers making MPF contributions in Hong Kong

      April 23, 2020
    • Alert

      HHS begins distributing $30B to health care providers affected by the pandemic under the CARES Act

      April 13, 2020
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • Cookie Preferences
    • Privacy Policy
    • Terms of Use
    • Accessibility Statement
    • Statement of Client Rights
    • Purchase Order Terms & Conditions
    • Nixon Peabody International LLC
    • PAL
    © 2025 Nixon Peabody. All rights reserved